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ABSTRACT
Objective: We have shown in vitro and in vivo that
osteoclast maturation requires calcium-release activated
calcium (CRAC) channels. In inflammatory arthritis,
osteoclasts mediate severe and debilitating bone
erosion. In the current study, we assess the value of
CRAC channels as a therapeutic target to suppress
bone erosion in acute inflammatory arthritis.
Methods: Collagen-induced arthritis (CIA) was
induced in mice. The CRAC channel inhibitor 3,4dichloropropionaniline (DCPA) and a placebo was
administered 1 day prior to collagen II booster to
induce arthritis. Effects on swelling, inflammatory cell
invasion in joints, serum cytokines and bone erosion
were measured.
Results: Assays, by blinded observers, of arthritis
severity showed that DCPA, 21 mg/kg/day, suppressed
arthritis development over 3 weeks. Bone and cartilage
damage in sections of animal feet was reduced
approximately 50%; overall swelling of joints was
reduced by a similar amount. Effects on bone density
by µCT showed clear separation in DCPA-treated CIA
animals from CIA without treatment, while differences
between controls without CIA and CIA treated with
DCPA differed by small amounts and in most cases
were not statistically different. Response was not
related to anticollagen titres. There were no adverse
effects in the treated group on animal weight or
activity, consistent with low toxicity. The effect was
maximal 12–17 days after collagen booster, during the
rapid appearance of arthritis in untreated CIA. At
20 days after treatment (day 40), differences in arthritis
score were reduced and tumour necrosis factor α,
interleukin (IL)-1, or IL-6 in the serum of the animals
were similar in treated and untreated animals.
Conclusions: DCPA, a novel inhibitor of CRAC
channels, suppresses bone erosion associated with
acute arthritis in mice and might represent a new
treatment modality for acute arthrits.

Rheumatoid arthritis (RA) has a chronic
relapsing course with bouts of acute arthritis
leading to destruction often of multiple
joints and usually requiring lifelong therapy.
While there are infectious causes of inﬂammatory arthritis and genetic predilections,

Key messages
What is already known about this subject?
▸ 3,4-dichloropropionaniline (DCPA) suppresses
arthritis development in the collagen-induced
arthritis (CIA) model.
▸ DCPA reduced bone and cartilage damage as
well as joint swelling by approximately 50% in
CIA animals.
▸ DCPA inhibited bone density reduction typically
noted in CIA animals.
▸ DCPA could provide a cost-effective, low toxicity
treatment for arthritis associated bone erosion in
humans.

typically RA also is idiopathic. Treatments for
inﬂammatory arthritis include antimetabolites, steroids and tumour necrosis factor α
(TNF-α)-blocking molecules all of which can
cause dangerous or debilitating side effects.1
We arrived at calcium-release activated
calcium current (CRAC) inhibitors as a
potential new means to treat acute arthritis
through a series of studies of the role of
calcium in osteoclast development. We found
that the IP3R receptor calcium channel was
necessary for osteoclast adhesion and activity,2 while others showed that IP3R-mediated
release of calcium was required for activation
of nuclear factor of activated T cells-1
(NFATc1)—a critical signal for osteoclast formation.3 We then demonstrated that osteoclastogenesis was dependent on CRAC
channels activated by release of calcium
stores: suppression of CRAC via siRNA or
inhibition by the CRAC antagonist,
3,4-dichloropropionaniline (DCPA) impaired
differentiation of bone degrading osteoclasts.4 Further, CRAC is required for normal
T-cell differentiation, also via NFATc1 activation.5 Thus a web of lymphocyte and macrophage differentiation events depend on
CRAC, all of which might be involved in arthritis progression.
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MATERIALS AND METHODS
Animal studies
Six-week old male DBA/1 mice were purchased from
Harlan Laboratories (Frederick MD) and housed in the
WVU vivarium. These animals were acclimated at least
1 week prior to any experimental use. All animal procedures were approved by the WVU Institutional Animal
Care and Use Committee.
Induction and assessment of arthritis
CIA was induced as described by Clutter et al.12 Brieﬂy,
bovine type II collagen (CII)(Elastin Products Co,
Owensville, Missouri, USA) was emulsiﬁed in complete
Freund’s adjuvant consisting of 10 mL of Freund’s
Incomplete Adjuvant (Difco Laboratories, Detroit,
Michigan, USA) plus 20 mg of Mycobacterium tuberculosis
H37RA (Difco Laboratories). The CII (100 µg per
animal; approximately 4 µg/kg) was injected intradermally on day 1 and 21 days later, a booster dose of
100 µg CII in Freund’s incomplete adjuvant (Difco
Laboratories) was administered. Inﬂammation was
apparent 4–8 days after the second dose, in 80% of
treated joints. At day 20 after primary immunisation,
time-release pellets (Innovative Research of America,
Sarasota FL) containing DCPA or the placebo, calibrated
to release the stated doses for 21 days, were placed
2

subcutaneously. Power analysis indicated that at least
eight animals per CIA group were required to provide a
valid statistical sample. Since induction of CIA does not
occur in 100% of the treated mice, 12 mice in each
CIA-induction group were initially started in the experiment. Treatment doses included 0 mg/kg ( placebo),
10.5 mg/kg/day of DCPA or 21 mg/kg/day of DCPA
were compared. Four untreated controls, that is, no CIA
or DCPA treatment, were also included.
Mice were monitored for arthritis and scored in a
blinded manner as described by Clutter et al.12 Brieﬂy,
swelling of paws was be graded on scale from 0 to 4 indicating number of swollen digits. All paws were evaluated,
so that the maximal arthritic index per mouse was 16.
Additionally, hind paw swelling was measured using
digital calipers on day 0, and each day on days 23–40.
Analysis of the bones and joints for arthritis was performed on H&E stained sections of hind paws, by
blinded observation. This scored synovial expansion and
inﬂammation, joint damage including pannus and bone
degradation, each on a scale of 0–3, with maximum
score of 9. For histological analysis, two paws from each
animal were analysed separately and blindly, and are calculated as two specimens per animal.
Serum analysis for antibodies and cytokines
Heart blood collected at the time of euthanasia on day
40 was used for analysis. Plasma was separated by centrifugation and frozen in aliquots at −20°C until used.
Production of anti-CII antibodies was evaluated by
ELISA (Rheumera, Astarte Biologics, Redmond,
Washington, USA) and cytokine concentrations were
measured using V–PLEX panels (Meso Scale Discovery,
Rockville, Maryland, USA) using the methods prescribed
by the respective manufacturers.
Antibody labelling of sections
Histological sections from the feet of animals euthanised
at 40 days, were stained using standard immunohistochemical methods to measure the effect of DCPA on
osteoclast bone interface and T-cell density. Osteoclast
bone interface density was determined by anti-ATPa3
(TCIRG) labelling, and the effect on CD3 T-cell density
was determined using anti-CD3 labelling. Anti-TCIRG1
quantiﬁcation was mouse monoclonal (clone 6H3) antibody (Sigma-Aldrich) at 1:100 dilution and CD3 quantiﬁcation used mouse monoclonal antibody anti-CD3
PC3/188A (raised against amino acids 156–168 of the
cytoplasmic domain of human CD3-ε) at a 1:100 dilution. Brieﬂy, sections were blocked in phosphatebuffered saline (PBS) with 2% hydrogen peroxide for
5 min, then in PBS with 2% bovine serum albumin
(BSA) for 2 h. The sections were incubated overnight
with antibodies at indicated concentrations in PBS with
0.01% tween 20. After washing, sections were incubated
for 1 h with biotinylated antimouse antibodies at 1:1000
dilution, washed again and incubated with streptavidinhorseradish peroxidase and diaminobenzidine substrate
Blair HC, et al. RMD Open 2016;1:e000093. doi:10.1136/rmdopen-2015-000093
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While total developmental suppression of CRAC
causes severe bone deformities and skeletal defects.6 In
adults, where skeletal development is mature, short-term
treatment is unlikely to cause major skeletal effects.
However, in long-term treatment immunological effects
are likely. Moreover, since the Th17 response important
to the pathogenesis of RA7 appears to be dependent on
the CRAC channel Orai18 9 we reasoned that partial
CRAC inhibition by DCPA might effectively blunt acute
arthritis. Although several CRAC inhibitors are known,
we pursued DCPA in part because of very low toxicity;
exposure of humans to DCPA in mg/kg quantities has
minimal apparent toxicity,10 although massive doses,
approximately
4–5 g/kg,
can
cause
fatal
methemoglobinaemia.11
We performed a trial of suppression of acute arthritis
using controlled-release DCPA, at 10.5 or 21 mg/kg/day,
in mice with acute collagen-induced arthritis (CIA).
DCPA caused a dramatic suppression of bone destruction and of articular inﬂammation at the higher dose.
The studies used blinded observation of joint swelling
over 5 weeks, and histological and μCT examination of
sections of bone in the feet. In addition, we studied
anticollagen antibodies and inﬂammatory cytokines,
which did not correlate with arthritis response at the
times studied. Osteoclast and T-cell numbers were also
examined by immunohistochemistry in affected joints
and while osteoclasts numbers were reduced, T-cells
were at similar density in inﬂammatory inﬁltrates in all
groups.

Animal models

μCT and morphometry
Analysis by μCT was as described.13 In brief, paws were
scanned on a Viva CT40 instrument (Scanco,
Bassersdorf, Switzerland) with three-dimensional (3D)
reconstruction by the manufacturer’s instrument-speciﬁc
software. The scan section increment was 20 μm; 3D
reconstruction used a density cut-off of 211 mg/cm3.
Analysis of trabecular thickness and trabecular spacing
used the plate model.
Statistics
Continuous data obtained at one time point (day 40),
such as anticollagen antibody titres, bone density, bone
volume, concentration of cytokines, osteoclast area and
per cent area of periosteal T cells, were analysed using
analysis of variance (ANOVA) followed by Dunnett’s
multiple comparison procedure (MCP) when the goal
was to compare the CIA-treated groups to untreated controls. In addition, Tukey-Kramer analysis with adjustment
for MCP and Fisher’s LSD was performed for continuous variables when the goal was to compare the differences among the CIA-treated groups. The hind paw
swelling data, recorded over time (day 0 and 23–40),
were analysed by the repeated measures ANOVA, using
the autoregressive autocorrelation structure and followed by Tukey-Kramer analysis with adjustment for
MCP. Data for anticollagen antibody titres and paw swelling were Ln-transformed and reciprocal squaretransformed, respectively, before ANOVA due to their
positive skewness. Data of categorical or ordinal nature,
such as arthritis index, were analysed by non-parametric
Kruskal-Wallis test for each day. In addition, arthritis
index data were grouped into two categories based on
the response, 0 for arthritis index equal to zero and 1
for all mice with arthritic index greater than 0. These
data were also analysed by Kruskal-Wallis test for each
day, followed by the non-parametric Wilcoxon rank sum
multiple comparison. A 60% power of statistical test was
based on the average arthritic index for each group and
the expected SD. Data were analysed using JMP and SAS
software (SAS Institute Inc, Cary, North Carolina, USA).
Signiﬁcance criterion α for all tests was 0.05.
RESULTS
In vivo analysis of CIA and the effect of DCPA treatment
by continuous-release subcutaneous pellets. Mice
showed no changes in body weight (data not shown), or
increased lethargy or overt stress in any group, although
severe inﬂammation of paws was induced by the CIA
protocol. As measured by the arthritic index scoring
each paw as 0–4 digits affected, on days 23–40 (after
Blair HC, et al. RMD Open 2016;1:e000093. doi:10.1136/rmdopen-2015-000093

booster injections at day 20), 80% of mice responded to
collagen injections by induction of arthritis (ﬁgure 1A).
The collagen-treated animals receiving placebo (0 mg/
kg/day DCPA) differed signiﬁcantly from untreated controls, as expected ( p<0.05 by Kruskal-Wallis test). The
effect of 10.5 mg/kg/day of DCPA was modest and at
most time points the results did not differ signiﬁcantly
by ANOVA from those of CIA animals treated with
placebo (0 mg/kg/day DCPA). On the other hand, a
dose of 21 mg/kg/day of DCPA reduced the arthritic
index, strongly before day 37 and 20–50% at days 38–40.
The arthritic index for animals treated with 21 mg/kg/
day was statistically lower from that of CIA animals
treated with placebo (Wilcoxon mean scores 14.5 vs 21,
respectively, p<0.05 by Wilcoxon test, scores not shown).
A scatter plot of the median arthritic scores of all
animals on day 37 (day of maximum effect) is shown in
ﬁgure 1B. In the CIA mice treated with 0 or 10.5 mg/
kg/day DCPA >50% of the animals showed arthritis
scores that variability was high. The majority of animals
treated in the CIA animals treated with 21 mg/kg/day
DCPA exhibited minimal arthritis scores, although three
animals showed signiﬁcant arthritis development. Hind
paw thickness (ﬁgure 1C) was also measured with the
average thickness for the untreated controls value of
2.29±0.03 mm. There were signiﬁcant effect of treatment
( p=0.02) and time ( p<0.01) (data not shown) on paw
thickness. Comparisons showed that on average,
CIA-treated, low-dose DCPA (10.5 mg/kg/day) as well as
placebo DCPA (0 mg/kg/day)-treated mice had signiﬁcantly thicker paws (2.56±0.04 mm), than the untreated
control mice ( p<0.05 for each comparison). Those
CIA-treated animals treated with 21 mg/kg/day DCPA
had a paw thickness of 2.43±.04 mm which was not signiﬁcantly different from the untreated controls
( p=0.52). There was a relatively high variability in the
data which likely reﬂects the all-or-none nature of arthritis; in some of the few mice treated with 21 mg/kg/day
DCPA that still developed arthritis, it was severe.
Analysis of CIA in sections of feet
Hind paws of animals were ﬁxed, decalciﬁed, parafﬁn
embedded, cut and stained with H&E (ﬁgure 2A–C).
Arthritis was scored by a blinded observer on a scale of
0–9, evaluating two paws per animal. Sections were
scored 0–3 for inﬂammation in periarticular tissue with
3 being suppurative inﬂammation, 0–3 for involvement
of cartilage and the joint space, with 3 requiring a
pannus and 0–3 for degradation of periarticular bone,
with 3 being full thickness destruction of the end plate.
Representative examples of paws from an untreated
animal showing no inﬂammation (ﬁgure 2A), a
DCPA-treated CIA animal showing measurable but not
severe arthritis (ﬁgure 2C), and a placebo-treated CIA
animal with severe disease (ﬁgure 2B) are shown. The
quantiﬁcation of arthritis severity by a blinded observer
is shown in ﬁgure 2D. The high-dose DCPA/CIA group
was statistically different from the CIA/placebo group
3
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for 5 min. H&E counterstaining was performed to show
tissue features. Imaging used a Nikon TE2000 inverted
microscope, with 14-bit 2048×2048 pixel monochrome
CCD camera and RGB ﬁlters to reconstruct colour
(Spot, Sterling Heights, Michigan, USA).
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μCT
There were clear erosions in CIA mice which were not
observed in high-dose DCPA-treated animals (ﬁgure 3A–
C), in accord with histology (ﬁgure 2A–C); high-dose
CIA/DCPA could not be distinguished visually from
untreated controls. Low-dose CIA/DCPA (10.5 mg/kg/
day) was not studied. Quantitative morphometry in the
paws, the most severely affected site in the skeleton,
showed that bone density and bone volume per total
volume was signiﬁcantly decreased in CIA/placebo mice.
The CIA/high-dose DCPA treatment group had density
indistinguishable from that of untreated controls (ﬁgure
3D) and showed a trend toward greater density than in
CIA/placebo mice ( p=0.08). The bone volume/total
volume for CIA/DCPA-treated mice did not differ from
that of untreated controls, and it was statistically greater
than for CIA/placebo animals ( p=0.03). Other parameters of bone morphometry including trabecular thickness and spacing were not different between groups
(data not shown). This reﬂects the fact that the damage
to the bone in arthritis is speciﬁc to the joints, which are
excluded
when
determining
bone
trabecular
parameters.
Figure 1 The effect of 3,4-dichloropropionaniline (DCPA)
treatment by continuous-release subcutaneous pellets on
collagen-induced arthritis (CIA) as measured by the arthritic
index. The data were gathered by a blinded observer. n=4 for
untreated controls; in the CIA animals n=11 for animals
treated with 0 mg/kg/day DCPA; n=10 for animals treated with
10.5 mg/kg/day DCPA; n=8 for animals treated with 21 mg/kg/
day. (A) Median effect relative to CIA animals treated with
0 mg/kg/day DCPA (blue; open circles) and untreated controls
(red; closed square). There is a trend toward efficacy at
intermediate times in CIA animals treated with 10.5 mg/kg/day
DCPA (green; closed circles) but only the CIA animals treated
with 21 mg/kg/day DCPA (yellow; closed triangles) had a
durable effect. (B) Scatter plot showing the arthritis scores at
day 37. This demonstrates that >50% animals in the CIA
animals treated with 0 mg/kg/day (blue; open circles) and
10.5 mg/kg/day DCPA (green; closed circles) show arthritis
scores that exceed the mean and several animals showed the
maximum arthritis score, whereas a majority of the animals
/21 mg/kg/day DCPA (yellow; closed triangles) showed no or
minimal arthritis scores. (C) Paw thickness, mean±SEM, for 4
control, 11 untreated CIA, and 8 high-dose DCPA/CIA
animals. The difference between control and CIA animals is
significant (*, p<0.05); the high-dose DCPA animals are not
different relative to the other groups (ns).

4

Effect of CIA with and without DCPA treatment on serum
inflammatory cytokines
We determined the effect of DCPA treatment on key
serum cytokines including TNF-α, IL-1 and IL-6. The
results showed strong induction of the cytokines by CIA
but, surprisingly, showed no effect of DCPA on cytokine
production despite strong suppression of arthritis by
DCPA (ﬁgures 1–3). Representative data from one of
two separate analyses with essentially identical results is
shown in ﬁgure 4. Interferon γ (IFN-γ), CXCL1, TNF-α,
IL-1β and IL-6 (ﬁgure 4A–E) were all signiﬁcantly
increased in CIA/placebo animals compared to the
untreated (no collagen injection) controls as expected.
TNF-α was also signiﬁcantly increased in the CIA/ highdose DCPA mice compared to untreated controls.
Comparison of CIA/placebo and CIA/high-dose DCPA
groups revealed no signiﬁcant reductions in any cytokines with CRAC inhibition. Based on these data, we
hypothesise that the inhibitory effect of DCPA on osteoclasts was not secondary to changes in systemic cytokine
levels, as these were not signiﬁcantly affected. Nor did
DCPA signiﬁcantly affect production of IL-12p70 or
Blair HC, et al. RMD Open 2016;1:e000093. doi:10.1136/rmdopen-2015-000093
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with p=0.024. The untreated group was statistically different from all other groups with p<0.01. Results for the
low dose (10.5 mg/kg/day) treatment group were
poorly separated from results for other CIA groups (the
low-dose DCPA-treated animals were therefore omitted
from further analyses). Figure 2E shows the anti-type II
collagen (CII) titres. Mean anti-CII titres in the 0 mg/
kg/day DCPA group were 7.1±2.1×103, 5.1±1.1×103 in
the 10.5 mg/kg/day DCPA group and 8.3±2.8×103 in the
21 mg/kg/day DCPA group; no signiﬁcant differences
among the CIA groups were found for anti-CII titres.

Animal models

IL-10, which also were measured (not shown). IL-17 was
also assayed but systemic levels were too low for meaningful comparisons (see Discussion).
Effect of CIA and DCPA on osteoclasts and T cells in
tissue sections
Antibody labelling for TCIRG1/ATPa3 was used to
determine the effect of the DCPA treatment on osteoclasts in tissue (ﬁgure 5A–D). TCIRG1 is the large
subunit of the osteoclast-membrane hydrogen pump; it
is not expressed by macrophages (nor in other cells in
Blair HC, et al. RMD Open 2016;1:e000093. doi:10.1136/rmdopen-2015-000093

the marrow); in contrast, enzymes including cathepsin K
and TRAP, which are highly expressed by osteoclasts and
often used as osteoclast markers, are also expressed in
macrophages and so are less speciﬁc.14 15 TCIRG1 labelling revealed a large and statistically signiﬁcant reduction in the bone surface area covered by osteoclasts in
CIA/DCPA-treated mice compared to CIA/placebo
mice (ﬁgure 5D). In contrast, anti-CD3 labelling showed
the density of T cells in inﬂammatory inﬁltrates to be
similar in the CIA/placebo and CIA/DCPA groups
(ﬁgure 5E).
5
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Figure 2 The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. (A–C) The
top frame shows an ankle bone in an untreated animal (untreated control, histological score 0). The middle frame shows severe
arthritis in CIA treated with 0 mg/kg/day DCPA, with severe synovial inflammation, pannus in the joint space and severe bone
degradation (histological damage score 8). The bottom frame shows the results from CIA animals treated with 21 mg/kg/day;
there is inflammation, with synovial thickening, but it is not severe (histological damage score 4). All fields are 1.2 mm across. (D)
Severity of arthritis in each group scored by a blinded observer based on sections as in A–C. The histological joint damage index
(HJDI) in CIA animals treated with 21 mg/kg/day DCPA (yellow bar) is statistically different from those treated with 0 mg/kg/day
(blue bar), p=0.024. The untreated group was different from all other groups, p<0.01. The CIA animals treated with 10.5 mg/kg/
day (green bar) were poorly separated on day 40 HJDI, and were not studied further. Both hind feet of each animal were
individually processed and blindly scored, so the number of measurements is twice the number of animals and expressed as the
mean±SEM HJDI. Animal numbers are as stated for figure 1. (E) Anti-type II collagen titre in CIA mice. The anti-type II collagen
titre in CIA animals treated with 21 mg/kg/day DCPA (yellow bar) was 8.3 (±2.8)×103 and was not statistically different from those
treated with 0 mg/kg/day (mean titre=7.1 (±2.1) × 103; blue bar). The mean anti-type II collagen titre of CIA animals treated with
10.5 mg/kg/day (green bar) was 5.1 (±1.1) × 103 and also was not statistically different from the other CIA animals. The anti-type
II collagen titres in the untreated group were all below the level of detection. Values shown are the respective group mean±SEM.
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DISCUSSION
We report an in vivo trial of a CRAC inhibitor on
inﬂammatory arthritis using the mouse CIA model.12
The theoretical basis for the observed effect is that
CRAC currents are essential to normal osteoclast development, and also are involved in T-cell activation which
also promotes arthritis.4 5 Our results include a highly
signiﬁcant decrease in joint swelling, inﬂammatory inﬁltrate and bone damage. Despite the manufacturer’s
statement that DCPA release is constant, it is likely that
the amount of released DCPA decreased during the
past days, when arthritis effect diminished (ﬁgure 1A).
These effects were independent from suppression of
serum cytokines, suggesting that the approach may
complement therapy that targets the inﬂammatory cytokines. The effects on many bone density and trabecular
bone parameters showed uniformly that DCPA reduced
the effects of CIA on bone health, although there was
variability in statistical signiﬁcance between individual
parameters. On the other hand, an important unresolved issue is that it is likely, indeed almost certain,
6
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Figure 3 μCT showing loss of bone in untreated animals
and effect of high-dose 3,4-dichloropropionaniline (DCPA).
(A–C) Examples of forelimb metacarpals in untreated mice,
CIA mice treated with 0 mg/kg/day and CIA mice treated with
21 mg/kg/day DCPA after euthanasia at day 40. Arrows in (B)
show cortical bone defects. (D–E) Bone density in total
volume of bone and bone volume per total volume in four
untreated controls and CIA animals treated with 0 (blue bar;
n=9) or 21 (yellow bar; n=9) mg/kg/day DCPA each. For both
measures the CIA animals treated with 0 mg/kg/day DCPA
has significantly reduced bone; the CIA animals treated with
21 mg/kg/day DCPA is not different from the untreated control
but is statistically greater than CIA animals treated with 0 mg/
kg/day in BV/V.

that at times with strongest arthritis suppression, effects
on cytokine levels would occur, or if DCPA treatment
were continued for longer times. In trabecular bone
density, bone volume/total volume and trabecular
spacing, the controls without were not statistically different from CIA treated with 21 mg/kg of DCPA, but CIA
without treatment was well separated statistically from
controls without CIA (ﬁgure 3). In further work, it will
also be useful to compare the new modality of CIA
treatment with other effective therapy as a positive
control.
The pore-forming unit of the CRAC channel is
Orai1,16 a four transmembrane-containing protein in
the plasma membrane that is activated primarily by the
endoplasmic-reticulum (ER) calcium sensor STIM1.17
Hence, in response to ER Ca2+ depletion, STIM1 translocates within the ER towards regions of close PM apposition where it interacts with Orai1.18 Using
electrophysiological CRAC measurement and ﬂuorescence analysis of STIM1/Orai1 association, we determined that DCPA inhibits CRAC channel activation by
destabilising STIM1/Orai1 interaction, leading to CRAC
channel closure.4 In that study, we further showed that
DCPA inhibits osteoclast formation in vitro; we now show
that that DCPA-induced CRAC channel inhibition leads
to inhibition of osteoclast formation and function in vivo
in an arthritis model.
Human Orai1 defects are now known, and are associated with defects including hypocalcaemia and muscular abnormalities.19 Although our mouse model
showed no signs of serious metabolic or muscular
anomaly, in larger animal studies it will be important
to monitor these parameters. Oddly, some Orai1 polymorphisms also are associated with increased serum
calcium and kidney disease, although the mechanisms
are unclear.20 A dysfunctional STIM1 mutation, that is,
in the calcium sensor required to activate Orai1 complexes, causes a syndrome with multiple developmental
defects including anaemia, asplenia, myopathy and ichthyosis.21 Orai1 is also implicated in respiratory and
neural development;22 23 in humans as in mice,6
complete absence of CRAC is probably lethal during
early development or soon after birth. However, after
normal development, at least for a time frame of
3–4 weeks, suppression of CRAC appears to be relatively benign.
Analysis of inﬂammatory cytokines showed that DCPA
treatment at 21 mg/kg/day did not affect TNF-α, IL-1,
IL-6, CXCL1, and IFN-γ (ﬁgure 4) all of which were
upregulated 2.5-fold to >10-fold by the CIA. We did not
detect signiﬁcant IL-17; other work has shown that IL-17
after adjuvant-induced arthritis, at 35 days, had serum
concentrations <1 ng/mL 35 days after arthritis induction, and which varied only approximately 20% between
untreated animals and arthritic animals,24 so it is likely
our assay was insufﬁciently sensitive to determine IL-17
effects. There is strong evidence for the involvement of
IL-17 in cellular signalling involved in induction of

Animal models

arthritis,25–28 but it is not a major secreted serum
protein; indeed, some amount of Orai1 signalling is
believed to be required to support TH17 cell development.8 Typically, IL-17 production is assayed in tissue
sections or cells, and further work will be needed to
resolve the contribution of IL-17 suppression to the
reduction of arthritis severity.
Recently, it was reported that another inhibitor of
store-operated
calcium
entry,
4-methy-4’-[3,5-bis
(triﬂuoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide, also called YM-58483 or BTP-2, at 10 mg/kg
suppressed CIA and suppressed inﬂammatory cytokines
IL-1, IL-6 and TNF-α to near-baseline levels at 10 days
after induction.29 While it is expected that other inhibitors of CRAC channels would function similarly in suppressing arthritis, the differences in response of
inﬂammatory cytokines are very interesting, although
not unexpected. The inhibitor BTP2 suppresses cytokines including IL-2 and calcium inﬂux by other
calcium channels, speciﬁcally TRPM4, at low nanomolar
concentrations.30 Overall, it is likely that BTP2 effects
Blair HC, et al. RMD Open 2016;1:e000093. doi:10.1136/rmdopen-2015-000093

overlap those of DCPA, but that BTP2 has a range of
effects that may be, at least in part, unrelated to CRAC
suppression. It will be important to test additional time
points to determine if DCPA has effects on some cytokines that were not resolved, but, importantly, at a time
when skeletal effects were clearly suppressed by DCPA,
IL-1, IL-6 and TNF-α were essentially identical in CIA
with and without DCPA treatment (ﬁgure 4).
The clear effect of DCPA treatment on arthritis,
despite no change in serum inﬂammatory factors, suggests that the direct blockade of CRAC activity by DCPA
mediates the reduction in osteoclast maturation. This
model (ﬁgure 6) will require further testing and reﬁnement. However, the independence of the DCPA effect
from suppression of the assayed serum inﬂammatory
cytokines suggests that Orai1 antagonists may be valuable modalities for treating inﬂammatory arthritis, and
possibly RA, by a mechanism independent of inﬂammatory cytokine suppression. However, serum cytokine
levels may not reﬂect the levels of these cytokines within
the joint spaces. It is likely that long-term strong
7
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Figure 4 Effect of CIA and treatment with 3,4-dichloropropionaniline (DCPA) on production of key serum inflammatory factors.
(A) IFN-γ. (B) CXCL1. (C) TNF-α. (D) IL-1β. (E) IL-6. One of two multiplex assays with similar results is shown. All of the
cytokines shown were induced strongly with the exception of IL-10 (not shown). No cytokines differed between CIA animals
treated with 0 (blue bar) or 21 mg/kg/day (yellow bar) DCPA. Statistical significance between groups is denoted by lower case
letters above the bar. Mean levels not connected by the same letter are significantly different at p<0.05. IFN-γ, Interferon γ; IL-6,
TNF-α, tumour necrosis factor α.

RMD Open

inhibition of CRAC would result in severe immunological or bone effects, based on the knockout mouse
phenotype,6 but treatment for several weeks had no
effect on animal health, activity, or weight.

In conclusion, treatment of CIA with 21 mg/kg/day of
DCPA dramatically suppressed bone erosion and bone
loss by μCT that is associated with CIA, with no apparent
effect on the general health of the animals or the
increase in serum inﬂammatory growth factors characteristic of acute arthritis. This remarkable ability of a
CRAC channel inhibitor to regulate bone erosion
without interfering with immune function may lead to a
valuable new tool for the treatment of inﬂammatory
arthritis.
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